[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100590624":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":11,"centralContacts":24,"locations":32,"responsibleParty":46,"collaborators":11,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":50,"sex":56,"minAge":57,"maxAge":11,"enrollmentInfo":58,"targetDuration":11,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":11,"overallStatus":34,"whyStopped":11,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Centre Oscar Lambret","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Clinical and Biological Collection","EXPERIMENTAL",null,[13,14],"Other: Constitution of a biological collection","Other: Assessment of Quality of Life and level of anxiety\u002Fdepression",[16,20],{"type":6,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"Constitution of a biological collection","* Left-over tissue samples (tumor tissue of different nature) frozen and secured in paraffin, and derived from standard care, are collected at study entrance until the end of oncologic treatment.\n* One blood sample of 28mL is collected once inclusion is confirmed",[9],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":11},"Assessment of Quality of Life and level of anxiety\u002Fdepression","Questionnaires QLQ-C30, OV-28 and HADS are completed by the patients after pre-registration, then after 3 and 6 cycles of systemic treatment, and every 3 months up to 2 years after pre-registration",[9],[25,30],{"name":26,"role":27,"phone":28,"phoneExt":11,"email":29},"Alicia Probst, PhD","CONTACT","33320295918","promotion@o-lambret.fr",{"name":31,"role":27,"phone":28,"phoneExt":11,"email":11},"Lucie BRESSON, MD, PhD",[33],{"facility":5,"status":34,"city":35,"state":11,"zip":11,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"RECRUITING","Lille","France","FR",{"type":39,"coordinates":40},"Point",[41,42],3.05512,50.63391,{"lat":42,"lon":41},[45],{"name":31,"role":27,"phone":28,"phoneExt":11,"email":11},{"type":47,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100590624","prospective-clinico-biological-database-of-patients-with-ovarian-andor-peritoneal-andor-fallopian-tube-carcinoma-100590624",false,"NCT06969833","Prospective Clinico-biological Database of Patients With Ovarian and\u002For Peritoneal and\u002For Fallopian Tube Carcinoma","Study of Prognostic Factors Associated With Overall Survival in Patients Initially Treated for Advanced Ovarian and\u002For Peritoneum and\u002For Fallopian Tubes Carcinoma: Analysis Using a Prospective Clinico-Biological Database","BCB-OVAIRE","Eligibility criteria for pre-registration:\n\n* Patient aged 18 or over\n* Informed consent warranted\n* Patient affiliated to a social security regimen\n* Suspected diagnosis of advanced and invasive ovarian cancer and\u002For primary peritoneal cancer and\u002For fallopian tube cancer (IIB to IV FIGO stages)\n* Pre-registration during standard care at the Oscar Lambret Centre, from diagnosis and before confirmation of definitive FIGO stage\n\nNon eligibility criteria for pre-registration:\n\n* Patient deprived of liberty or under curatorship or guardianship\n* Refusal to participate\n\nInclusion criteria:\n\n• Confirmed diagnosis of advanced and invasive ovarian cancer and\u002For primary peritoneal cancer and\u002For fallopian tube cancer (IIB to IV FIGO stages)\n\nExclusion criteria:\n\n• Dismissed diagnosis of advanced and invasive ovarian cancer and\u002For primary peritoneal cancer and\u002For fallopian tube cancer , or other type of cancer","FEMALE","18 Years",{"count":59,"type":60},371,"ESTIMATED","INTERVENTIONAL",[63],"NA","Cancer of the ovary and\u002For peritoneum and\u002For fallopian tube have a very poor prognosis, and require the implementation of collaborative research tools and new innovative therapies. The main objective of this study is to implement prognostic model of overall survival on patients included prospectively as part of the initial treatment of advanced ovarian and\u002For peritoneum, and\u002For fallopian tubes carcinoma (this cohort corresponds to the \"Turquoise\" care pathway of the Oscar Lambret Center) regardless of the treatment carried out,, integrating both patient's and tumor's characteristics. A clinical and biological database is implemented for this purpose.\n\n371 patients will be recruited over a 5-year period at the Oscar Lambret Center.\n\nThe active participation of each patient will be 2 years (from the date of pre-registration until the end of study participation, defined by the date of the last intervention specific to the research), then the data from standard care and survival data will be collected until the last follow-up of the last patient, 2 years after the last pre-registration.",[66,67,68],"Cancer of the Ovary","Cancer of the Fallopian Tube","Peritoneal Cancer","2026-03-25",{"date":71,"type":72},"2026-03-30","ACTUAL",{"date":74,"type":72},"2025-06-27",{"date":76,"type":60},"2032-06-27",{"name":5,"class":6},1]